Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Rivalry with Pfizer starting to take shape. First market mover advantage is a stop-gap measure.

Merck's Plan B Percolates After Pfizer Announces Dominance

Acceleron Pharma

There's nothing to worry about with a recent delay.

Is Merck's Planned Acquisition of Acceleron in Trouble?

Merck reported a robust FQ3 report card that easily beat the topline and bottom line. Its COVID-19 oral antiviral treatment has also been gaining traction, as it secured its approval from the UK government.

How Will Merck's Stock Forecast Be Impacted By U.K.'s COVID Pill Authorization?

MERCK Kommanditgesellschaft auf Aktien (MKGAF) CEO Belén Garijo on Q3 2021 Results - Earnings Call Transcript

Japan's government is set to purchase 1.6 million courses of Merck's (MRK) oral pill for COVID-19, molnupiravir, if approved or authorized.

Merck (MRK) Inks $1.2B COVID-19 Pill Supply Deal With Japan

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Initiation of VICTOR Ph3 Study Evaluating VERQUVO

Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event

Germany's Merck KGaA, which is investing to catch up with ballooning demand for its biotech manufacturing supplies, said the order book in COVID-19 related lab gear was still growing faster than sales but it was getting a better handle on the situation.

Merck says making progress on meeting surge in lab gear demand

Germany's Merck KGaA said its Life Science unit, which supplies materials and gear to makers of vaccines and drugs, saw adjusted earnings jump 30.7% in the third quarter, driven by demand related to COVID-19.

Merck KGaA's lab supplies unit sees Q3 EBITDA jump 30.7%

Merck MRK, +0.05% and privately held Ridgeback Biotherapeutics said Wednesday the Japanese government has agreed to purchase $1.6 million courses of their COVID-19 antiviral molnupiravir, once it receives an authorization or approval. Merck and Ridgeback have applied for authorization of the treatment from the U.S. Food and Drug Administration, Japan's Pharmaceuticals and Medical Devices Agency and the European Medicines Agency.

Merck and Ridgeback Biotherapeutics say Japan to purchase 1.6 million courses of their COVID antiviral if it's authorized

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck & Ridgeback Announce Japanese Govt to Purchase 1.6 Million Courses of Molnupiravir Investigational COVID-19 Medicine Upon Authorization/Approval

Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval

The purchase brings the total U.S. supply of the drug to 3.1 million courses, assuming the pill is approved by regulators.

U.S. Inks $1 Billion Deal For Extra Doses Of Merck's Antiviral Covid Pill

The U.S. government will buy another $1 billion worth of Merck & Co Inc (NYSE: MRK) and partner Ridgeback Biotherapeutics' COVID-19 pills. The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.

US Government To Purchase Additional 1.4M Doses Of Merck's COVID-19 Pill

Pfizer

Better COVID Stock: Merck vs. Pfizer

Merck fell almost 10% on Friday after Pfizer announced its own antiviral pill.

Merck Stock Still Looks Attractive Despite Pfizer Competition

Shares of Merck & Co. Inc. MRK, +1.31% rallied 1.9% in premarket trading Tuesday, after the drug maker and partner Ridgeback Biotherapeutics said the U.S. government will exercise options to buy 1.4 million additional courses of the companies' antiviral pill molnupiravir for $1 billion if the COVID-19 treatment is either granted Emergency Use Authorization or approved by the Food and Drug Administration. That brings the total commitment from the U.S. government to 3.1 million course of molnupiravir for $2.2 billion, between authorization and early 2022.

Merck stock rallies after U.S. plans to buy 1.4 million more COVID-19 pill courses for $1 billion if authorized

Walgreens

The Dow Jones Industrial Average is home to a trio of deeply discounted value stocks.

3 Dow Stocks That Are Screaming Buys in November

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)---- $MRK #MRK--Merck and Ridgeback Announce US Govt to Purchase 1.4 Million Additional Courses of Molnupiravir Investigational Antiviral for treatment of COVID-19

Merck and Ridgeback Announce U.S. Government to Purchase 1.4 Million Additional Courses of Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults

Bangladesh's Beximco Pharmaceuticals Ltd said on Tuesday it would begin selling a generic version of Merck's antiviral pill for COVID-19 following emergency use authorisation from national regulators.

Asian firm Beximco to sell generic version of Merck COVID-19 pill

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.

Merck Announces Receipt of Antitrust Clearance in Germany and Austria Relating to Tender Offer to Acquire Acceleron Pharma Inc.

The European Union is negotiating with Merck & Co Inc (NYSE: MRK) and Pfizer Inc (NYSE: PFE) over possible contracts to supply COVID-19 drugs, an EU official told Reuters. Both the companies have developed antiviral pills that have shown promising efficacy in trials of adults with COVID-19 who are at high risk of serious illness, with Pfizer's at 89% and Merck's around 50%.

Merck Ahead Of Pfizer In Talks With Europe For COVID-19 Pills: Reuters

BioNTech SE

Moderna

Now that the COVID-19 vaccine is available to virtually everyone in the country, I have one favorite among vaccine stocks after earnings. The post Are Vaccine Stocks A Buy On Earnings?

Are Vaccine Stocks A Buy On Earnings?

The pharma giant's stock took flight last month after its oral COVID-19 therapy hit the mark in a pivotal trial.

Here's Why Merck Stock Vaulted Higher in October

CBRE Group

Gartner

Nucor

ON Semiconductor

Tesla

We have narrowed down our search to five large-cap growth stocks that have strong growth potential for the rest of 2021. These are: TSLA, NUE, ON, IT and CBRE.

Three Encouraging News on U.S. Economic Recovery: 5 Top Picks

The stock price of Merck & Co., Inc. (NYSE: MRK) fell over 9% in the previous trading session. This is why it happened.

Merck (MRK) Stock: Why The Price Fell

AbbVie

Bristol-Myers

These companies could both diversify your portfolio and boost your dividend income.

News for Merck Stock (MRK)